vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and M-tron Industries, Inc. (MPTI). Click either name above to swap in a different company.

M-tron Industries, Inc. is the larger business by last-quarter revenue ($14.2M vs $13.5M, roughly 1.1× Assertio Holdings, Inc.). On growth, M-tron Industries, Inc. posted the faster year-over-year revenue change (11.2% vs -57.9%). Over the past eight quarters, M-tron Industries, Inc.'s revenue compounded faster (12.8% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

M-tron Industries, Inc. designs, manufactures and markets high-performance frequency control and timing solutions including crystal oscillators, filters and integrated timing assemblies. Its products serve aerospace, defense, telecom, industrial automation and medical device segments, catering mainly to North American, European and Asian commercial and government clients.

ASRT vs MPTI — Head-to-Head

Bigger by revenue
MPTI
MPTI
1.1× larger
MPTI
$14.2M
$13.5M
ASRT
Growing faster (revenue YoY)
MPTI
MPTI
+69.1% gap
MPTI
11.2%
-57.9%
ASRT
Faster 2-yr revenue CAGR
MPTI
MPTI
Annualised
MPTI
12.8%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
MPTI
MPTI
Revenue
$13.5M
$14.2M
Net Profit
$3.4M
Gross Margin
Operating Margin
-86.7%
27.3%
Net Margin
24.1%
Revenue YoY
-57.9%
11.2%
Net Profit YoY
60.1%
EPS (diluted)
$-4.54
$0.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
MPTI
MPTI
Q4 25
$13.5M
$14.2M
Q3 25
$49.5M
$14.2M
Q2 25
$29.2M
$13.3M
Q1 25
$26.5M
$12.7M
Q4 24
$32.2M
$12.8M
Q3 24
$29.2M
$13.2M
Q2 24
$31.1M
$11.8M
Q1 24
$32.4M
$11.2M
Net Profit
ASRT
ASRT
MPTI
MPTI
Q4 25
$3.4M
Q3 25
$11.4M
$1.8M
Q2 25
$-16.4M
$1.6M
Q1 25
$-13.5M
$1.6M
Q4 24
$2.1M
Q3 24
$-2.9M
$2.3M
Q2 24
$-3.7M
$1.7M
Q1 24
$-4.5M
$1.5M
Operating Margin
ASRT
ASRT
MPTI
MPTI
Q4 25
-86.7%
27.3%
Q3 25
23.2%
18.0%
Q2 25
-27.5%
13.9%
Q1 25
-50.0%
15.8%
Q4 24
-41.9%
20.1%
Q3 24
-10.4%
22.1%
Q2 24
-11.6%
17.8%
Q1 24
-13.4%
16.0%
Net Margin
ASRT
ASRT
MPTI
MPTI
Q4 25
24.1%
Q3 25
23.1%
12.9%
Q2 25
-56.0%
11.7%
Q1 25
-51.1%
12.8%
Q4 24
16.7%
Q3 24
-10.0%
17.2%
Q2 24
-11.8%
14.8%
Q1 24
-13.9%
13.3%
EPS (diluted)
ASRT
ASRT
MPTI
MPTI
Q4 25
$-4.54
$0.90
Q3 25
$0.11
$0.63
Q2 25
$-0.17
$0.53
Q1 25
$-0.14
$0.56
Q4 24
$-3.28
$0.68
Q3 24
$-0.03
$0.81
Q2 24
$-0.04
$0.63
Q1 24
$-0.05
$0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
MPTI
MPTI
Cash + ST InvestmentsLiquidity on hand
$63.4M
$20.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$63.2M
Total Assets
$267.0M
$68.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
MPTI
MPTI
Q4 25
$63.4M
$20.9M
Q3 25
$93.4M
$18.3M
Q2 25
$98.2M
$15.5M
Q1 25
$87.3M
$13.7M
Q4 24
$100.1M
$12.6M
Q3 24
$88.6M
$8.5M
Q2 24
$88.4M
$6.5M
Q1 24
$80.7M
$5.4M
Total Debt
ASRT
ASRT
MPTI
MPTI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
MPTI
MPTI
Q4 25
$94.0M
$63.2M
Q3 25
$105.8M
$37.0M
Q2 25
$93.3M
$34.8M
Q1 25
$108.5M
$33.2M
Q4 24
$121.1M
$31.3M
Q3 24
$130.5M
$26.2M
Q2 24
$132.2M
$23.7M
Q1 24
$134.5M
$21.7M
Total Assets
ASRT
ASRT
MPTI
MPTI
Q4 25
$267.0M
$68.4M
Q3 25
$319.8M
$42.2M
Q2 25
$273.8M
$39.7M
Q1 25
$286.4M
$37.8M
Q4 24
$284.7M
$36.6M
Q3 24
$276.0M
$31.5M
Q2 24
$279.4M
$28.4M
Q1 24
$282.0M
$26.8M
Debt / Equity
ASRT
ASRT
MPTI
MPTI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
MPTI
MPTI
Operating Cash FlowLast quarter
$-30.0M
$2.7M
Free Cash FlowOCF − Capex
$2.3M
FCF MarginFCF / Revenue
16.4%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
0.78×
TTM Free Cash FlowTrailing 4 quarters
$8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
MPTI
MPTI
Q4 25
$-30.0M
$2.7M
Q3 25
$-4.8M
$3.5M
Q2 25
$19.1M
$2.9M
Q1 25
$-12.5M
$1.6M
Q4 24
$11.5M
$1.8M
Q3 24
$-35.0K
$2.3M
Q2 24
$7.4M
$2.0M
Q1 24
$7.5M
$1.5M
Free Cash Flow
ASRT
ASRT
MPTI
MPTI
Q4 25
$2.3M
Q3 25
$2.7M
Q2 25
$2.0M
Q1 25
$1.0M
Q4 24
$1.4M
Q3 24
$1.8M
Q2 24
$1.1M
Q1 24
$1.4M
FCF Margin
ASRT
ASRT
MPTI
MPTI
Q4 25
16.4%
Q3 25
19.1%
Q2 25
15.4%
Q1 25
8.0%
Q4 24
10.8%
Q3 24
13.4%
Q2 24
9.2%
Q1 24
12.3%
Capex Intensity
ASRT
ASRT
MPTI
MPTI
Q4 25
2.4%
Q3 25
5.7%
Q2 25
6.1%
Q1 25
4.6%
Q4 24
3.3%
Q3 24
0.0%
3.6%
Q2 24
7.4%
Q1 24
1.1%
Cash Conversion
ASRT
ASRT
MPTI
MPTI
Q4 25
0.78×
Q3 25
-0.42×
1.92×
Q2 25
1.83×
Q1 25
0.99×
Q4 24
0.85×
Q3 24
0.99×
Q2 24
1.12×
Q1 24
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

MPTI
MPTI

US$11.3M79%
Non Us$2.9M21%

Related Comparisons